9:07 pm · 13 April 2021

Daily summary: Global stocks mixed after J&J vaccine pause

OIL.WTI
Commodities CFDs
-
-
J&J
Cash Stocks
JNJ.US, Johnson & Johnson
-
-
US30
Indices CFDs
-
-

  • European stocks flat on mixed economic data
  • Stronger than expected inflation rate for the US
  • FDA pauses Johnson & Johnson Covid-19 vaccine

European indices finished today's session flat amid mixed economic data. Investor's morale in Germany fell in April for the first time since last November, as private consumption expectations declined due to the concerns of a stricter lockdown. At the same time, China's foreign trade data showed that the recovery of the second largest economy country is moving forward, with imports rising the most in four years to an all-time high.

US indices are trading mixed, with the Dow Jones down more than 0.50% and the S&P 500 little changed after hitting a new intraday high while the Nasdaq rose almost 1%  as the US consumer price inflation rate increased more than expected in March to the highest level since August 2018. However, upward potential was capped by news that FDA called for a pause in the use of Johnson & Johnson (JNJ.US) Covid-19 vaccine over blood clotting issues. The yield on the benchmark 10-year Treasury note continued to decline and reached 1.63% level after a solid auction for 30-year bonds.

WTI crude rose more than 0.75% and is trading slightly above $60.00 a barrel, while Brent is trading nearly 0.6% higher around $63.80 a barrel amid renewed tensions in the Middle East where the Houthi movement reportedly fired missiles on Saudi oil sites. Investors now await the weekly API report which will be published later in the day and  EIA figures on Wednesday, with markets anticipating US stocks fell for the third straight week. Elsewhere gold rose nearly 0.9% to $ 1,747.00 / oz, while silver is trading 2.0 % higher, around $ 25.30 / oz as the dollar index fell to around a 3-week low.

WTI crude (OIL.WTI) failed to break above the upper limit of the triangle formation and pulled back slightly. Should downbeat moods prevail, support at $59.03 may come into play. On the other hand, if buyers will manage to finally break higher, then upward impulse could be extended towards resistance at $61.92. Source: xStation5

16 October 2025, 8:17 pm

J.B. Hunt gains 18% after strong quarterly results 🚀

16 October 2025, 7:05 pm

Breaking: crude oil inventories above expectations 📌

16 October 2025, 5:36 pm

BREAKING: NATGAS declines after EIA data 📌

16 October 2025, 5:28 pm

Stock of the Week - Lam Research Corp (16.10.2025)

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Join over 1 700 000 XTB Group Clients from around the world.